Skip to main content

Table 1 Composition of PCCs in the World Federation of Hemophilia register of clotting factor concentrates

From: Erratum to: Clinical review: Prothrombin complex concentrates - evaluation of safety and thrombogenicity

  

International units relative to factor IX

  

Brand name

Manufacturer

Factor II

Factor VII

Factor IX

Factor X

Viral inactivation

Additional information

Bebulin VH

Baxter BioScience, Austria

120

(13)

100

100

Vapour heat, 60°C for 10 hours at 190 mbar, then 80°C for 1 hour at 375 mbar

Heparin added

Beriplex P/N

CSL Behring, Germany

128

68

100

152

Pasteurisation at 60°C for 10 hours, and nanofiltration

Protein C; antithrombin, heparin and albumin added

Cofact

Sanquin, the Netherlands

56-140

28-80

100

56-140

Solvent/detergent and 15 nm nanofiltration

Antithrombin added

KASKADIL

LFB, France

148

40

100

160

Solvent/detergent

Heparin added

Octaplex

Octapharma, Austria and France

44-152

36-96

100

50

Solvent/detergent and nanofiltration

Heparin added; low activated factor VII content

Profilnine SD

Grifols, USA

148

(11)

100

64

Solvent/detergent

-

Prothrombinex VF

CSL Bioplasma, Australia

100

(-)

100

100

Dry heat, 80°C for 72 hours and nanofiltration

Antithrombin and heparin added

Prothromplex T

Baxter BioScience, Austria

100

85

100

100

Vapour heat, 60°C for 10 hours at 190 mbar, then 80°C for 1 hour at 375 mbar

Antithrombin and heparin added

UMAN Complex D.I.

Kedrion, Italy

100

(-)

100

80

Solvent/detergent and dry heat, 100°C for 30 minutes

Antithrombin and heparin added

  1. Composition of prothrombin complex concentrates (PCCs) listed in the World Federation of Hemophilia register of clotting factor concentrates [54], excluding concentrates for national markets only or for which the concentrations of factors relative to factor IX were not available from the relevant product information sheets. Factor VII presented in parentheses for three-factor PCCs.